Table 1. Patient characteristics.
| Variables | Group 1 | Group 2 | Total | P value |
|---|---|---|---|---|
| N (%) | 53 (81.5) | 12 (18.5) | 65 | |
| Age (year) | 59.30±10.52 | 57.00±12.40 | 58.88±10.82 | 0.510 |
| Sex (F: M), (%) | 16 (30.2):37 (69.8) | 3 (25.0):9 (75.0) | 19 (29.0):46 (71.0) | 1.000 |
| Resection margin (mm) | 4.09±1.97 | 11.33±4.74 | 5.43±3.88 | < 0.001 |
| Metastatic nodule size (largest diameter, mm) | 13.15±6.73 | 9.83±3.88 | 12.54±6.41 | 0.106 |
| Metastatic nodule depth (deepest length from periphery, mm) | 19.19±8.83 | 13.33±6.99 | 18.11±8.78 | 0.036 |
| Disease-free interval (month) | 18.75±20.94 | 9.17±12.28 | 16.98±19.9 | 0.133 |
| Serum CEA (ng/mL) | 2.25±2.39 | 2.75±2.77 | 2.34±2.45 | 0.524 |
| VATS (%) | 53 (100.0) | 12 (100.0) | 65 | – |
| Visceral pleura involvement (%) | 12 (22.6) | 6 (50.0) | 18 | 0.077 |
| Chemotherapy (%) | ||||
| Preoperative | 34 (64.2) | 10 (83.3) | 44 | 0.309 |
| Postoperative | 40 (75.5) | 11 (91.7) | 51 | 0.436 |
| Radiotherapy (%) | ||||
| Preoperative | 8 (15.1) | 2 (16.7) | 10 | 1.000 |
| Postoperative | 6 (11.3) | 2 (16.7) | 8 | 0.634 |
Group 1: patients with resection margin length between 1 to 10 mm or shorter than the tumor size; Group 2: patients with resection margin length greater than 10 mm or at least greater than the tumor size. F, female; M, male; CEA, carcinoembryonic antigen; VATS, video-assisted thoracoscopic surgery.